Home
Off-the-shelf
Cell lines

Cell lines

Our humanized & Knockout ICP cell lines can be used for in vivo tumor growth assays in syngeneic models and in vitro mechanistic studies.

Immune checkpoint cell lines

Our humanized and Knockout immune checkpoint cell lines represent cutting-edge advancements in the field of immuno-oncology research. These meticulously engineered cell lines play a pivotal role in unraveling the complexities of immune responses and checkpoint regulation.

The Humanized cell lines are tailored to express human immune checkpoint proteins, providing a more accurate reflection of human immune system behavior.

On the other hand, the Knockout cell lines involve the targeted inactivation of specific immune checkpoint genes, allowing researchers to study the effects of these alterations on immune function.

These innovative cell lines serve as invaluable tools for exploring the intricate mechanisms of immune checkpoint pathways, paving the way for advancements in immunotherapy and contributing significantly to the development of novel therapeutic strategies.

Discover our

Cell lines

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

CT26-Pd-l1-ko

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

Immune checkpoint
PD-L1
CT26

MC38-Pd-l1-ko

The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

PD-L1
Immune checkpoint

MC38-hPD-L1-hHER2-LZ

The  MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.

MC38
Immune checkpoint
PD-L1
HER2

MC38-hPD-L1-LZ

The MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

PD-L1
Immune checkpoint
MC38
PD-1

MC38-hCD39-LZ

The  MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form  infiltrated tumors in immunocompetent mice.

CD39
MC38
Immune checkpoint

EL4-hCD20-LZ

The  EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.

CD20
Immune checkpoint
EL4

EL4-hCD19-LZ

EL4-hCD19-LZ cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

CD19
EL4
Immune checkpoint

CT26-hEpCAM-LZ

CT26-hEpCAM-LZ  clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.

CT26
Immune checkpoint
EpCAM

CT26-hCD39-LZ

The CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.

CT26
Immune checkpoint
CD39

CT26-hPD-L1

The humanized PD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.

PD-L1
Immune checkpoint

MC38-hPD-L1-hCD47-LZ

The MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.

MC38
Immune checkpoint
PD-L1
CD47

Discover our customized models

Learn  more

Related resources and publications

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

pain research

nutrition

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
PosterS
(
0
)
Scientific Articles
(
0
)
CommentarIes
(
0
)
Case studies
(
0
)
No results
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

Eur J Nucl Med Mol Imaging

Jul 2024
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

Front Immunol

Dec 2023
Highlighted article
read the comment
CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

PLoS One

Jan 2023
Highlighted article
read the comment
ERα-36 regulates progesterone receptor activity in breast cancer

Breast Cancer Res

Jan 2020
T cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer

Immunology

Jan 2020
SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2.

Nat Immunol

Jan 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Cancer Immunol Res

Jan 2019
iPS technology: Four factors that will change the world… some day

iPS technology

5 min read
-
Nov 2017
Improving in vitro models: the coming of age of organoids

Organoids

6 min read
-
Mar 2018
Syngeneic mouse models

Customized mouse model

3 min read
-
Apr 2020
Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

5 min read
-
Aug 2021
A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read
-
Jul 2022
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read
-
Jun 2023
Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

10 min read
-
Mar 2024
No results
No results

Other categories

Immunodeficient rodents

Explore our immunodeficient models, featuring cutting-edge strains like BRGSF mouse and SDRG rat.
Learn more

Humanized mice (HIS/human immune system)

Address human-specific questions in a more relevant manner, facilitating translational research in several biomedical disciplines and approaches.
Learn more

Knockout and reporter models

Our off-the-shelf Knockout & reporter models are well established, validated and widely used mouse and rat lines.
Learn more

Humanized mice (target-specific)

Well-established mouse lines that allow in vivo efficacy and safety assessment of biologics and other compounds.
Learn more